- Home
- ROIV vs WCC Comparison
ROIV vs WCC Comparison
Compare ROIV & WCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- WCC
- Stock Information
- Founded
- ROIV 2014
- WCC 1922
- Country
- ROIV United Kingdom
- WCC United States
- Employees
- ROIV N/A
- WCC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- WCC Telecommunications Equipment
- Sector
- ROIV Health Care
- WCC Consumer Discretionary
- Exchange
- ROIV Nasdaq
- WCC Nasdaq
- Market Cap
- ROIV 8.4B
- WCC 8.0B
- IPO Year
- ROIV N/A
- WCC 1999
- Fundamental
- Price
- ROIV $10.91
- WCC $166.25
- Analyst Decision
- ROIV Buy
- WCC Buy
- Analyst Count
- ROIV 4
- WCC 7
- Target Price
- ROIV $17.50
- WCC $216.57
- AVG Volume (30 Days)
- ROIV 5.5M
- WCC 689.8K
- Earning Date
- ROIV 05-29-2025
- WCC 05-01-2025
- Dividend Yield
- ROIV N/A
- WCC 1.08%
- EPS Growth
- ROIV N/A
- WCC 10.34
- EPS
- ROIV N/A
- WCC 13.26
- Revenue
- ROIV $122,585,000.00
- WCC $21,812,500,000.00
- Revenue This Year
- ROIV N/A
- WCC $4.13
- Revenue Next Year
- ROIV N/A
- WCC $4.27
- P/E Ratio
- ROIV N/A
- WCC $12.62
- Revenue Growth
- ROIV 140.04
- WCC N/A
- 52 Week Low
- ROIV $8.73
- WCC $125.21
- 52 Week High
- ROIV $13.06
- WCC $216.17
- Technical
- Relative Strength Index (RSI)
- ROIV 52.03
- WCC 52.45
- Support Level
- ROIV $10.58
- WCC $168.06
- Resistance Level
- ROIV $11.77
- WCC $173.17
- Average True Range (ATR)
- ROIV 0.33
- WCC 4.32
- MACD
- ROIV -0.04
- WCC 0.51
- Stochastic Oscillator
- ROIV 28.57
- WCC 49.21
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About WCC WESCO International Inc.
Wesco International is an industrial distributor that has three reportable segments, electrical and electronic solutions, communications and security solutions, and utility and broadband solutions. The company offers more than 1.5 million products to its 140,000 active customers through a distribution network of 800 branches, warehouses, and sales offices, including 43 distribution centers. Wesco generates approximately 74% of its sales in the United States, but it has a global reach, with operations in 50 other countries.